
Amylyx Begins Phase 1 LUMINA Study of CAPN2-Targeting Agent for ALS
Dosing has begun for a new phase 1, placebo-controlled study (NCT06665165) testing Amylyx Pharmaceuticals’ AMX0114, investigational antisense oligonucleotide (ASO) targeting calpain-2 (CAPN2), in patients with amyotrophic lateral sclerosis (ALS). Dubbed …